52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
EMA Says Latest Safety Data For Pfizer's COVID-19 Vaccine In Line With Known Benefit-Risk Profile
U.S. FDA Expands Approval Of Pfizer’S LORBRENA For ALK-Positive Metastatic Lung Cancer
Health Canada Allows More Flexible Storage And Transportation Conditions For Pfizer-Biontech COVID-19 Vaccine
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Biotechnology & Drugs
235 E 42ND ST
NEW YORK, NY
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'Amelio
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Group President, Pfizer Biopharmaceuticals Group
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The United States has administered 85,008,094 doses of COVID-19 vaccines as of Friday morning and delivered 114,133,115 doses, the Centers for Disease Control and Prevention said.
* PFIZER WILL MOVE UP DELIVERIES OF COVID-19 VACCINE TO CANADA, SENDING ADDITIONAL 1.5 MILLION DOSES IN MARCH AND ANOTHER 1 MILLION DOSES IN BOTH APRIL AND MAY - PRIME MINISTER TRUDEAU Source text for Eikon: Further company coverage: [ ] (Reporting by David Ljunggren)
Rwanda began its COVID-19 vaccine campaign on Friday, becoming the first nation in Africa to use pharmaceutical company Pfizer's doses that require ultra-cold storage.
Takeda Pharmaceutical said it had asked regulators to approve use of Moderna's COVID-19 vaccine on Friday, which would add a third option to Japan's vaccination programme.
The minister overseeing Japan's vaccination programme, Taro Kono, said on Friday shipments to Japan of COVID-19 vaccine developed by Pfizer Inc and BioNTech will likely make a nearly fourfold jump in April from the previous month.
South Africa's medicines regulator said on Thursday that it was at an advanced stage of reviewing an emergency use application for Pfizer's COVID-19 vaccine.
South Korea's drug safety ministry said on Friday it has granted final approval for the use of Pfizer's coronavirus vaccine.
The United States has administered 82,572,848 doses of COVID-19 vaccines as of Thursday morning and delivered 109,905,530 doses, the Centers for Disease Control and Prevention said.
South Africa's drug regulatory authority SAHPRA told Reuters on Thursday that an emergency use application for Pfizer's COVID-19 vaccine was "in advanced stages of review". (Reporting by Wendell Roelf Editing by Alexander Winning)
* EMA SAYS LATEST SAFETY DATA FOR PFIZER'S COVID-19 VACCINE ARE IN LINE WITH THE KNOWN BENEFIT-RISK PROFILE
Recent data on COVID-19 vaccinations with the Pfizer/BioNTech and AstraZeneca shots are encouraging, the European regional adviser to the World Health Organization told reporters on Thursday.
Brazil set a daily record for COVID-19 deaths for a second straight day on Wednesday, as a raging resurgence of the virus led Sao Paulo state to shutter businesses and the government to try to close vaccine deals with Pfizer and Janssen.
The United States has administered 80,540,474 doses of COVID-19 vaccines as of Wednesday morning and delivered 107,028,890 doses, the Centers for Disease Control and Prevention said.
The Brazilian government has reached an agreement to buy 100 million doses of Pfizer Inc's COVID-19 vaccine, Globo News cable channel reported on Wednesday.
The Czech Republic and Slovakia, both under severe pressure from the coronavirus pandemic, will each receive an extra 100,000 doses of Pfizer/BioNTech vaccine from their European Union partners.
Kenya received over a million doses of the AstraZeneca COVID-19 vaccine on Wednesday, while Rwanda said it was the first in Africa to secure shots from Pfizer, as efforts to inoculate the world's poorest nations accelerated.
British scientists urged European countries to take note on Wednesday of interim data showing what they described as "remarkable" effectiveness of a single dose of Pfizer's or AstraZeneca's COVID-19 vaccines in frail and elderly people.
Austria will receive an extra 100,000 doses of Pfizer's coronavirus vaccine to administer to all adults in a hotspot of the South African variant and carry out a study there on the drug's efficacy, the government said on Wednesday.
One dose of either Pfizer-BioNTech's or AstraZeneca's COVID-19 vaccine helps to prevent disease severe enough to require hospitalisation of people in their 80s with other illnesses, interim data from a UK study showed on Wednesday.
The first doses of the Pfizer COVID-19 shots to be dispatched to Africa under the global COVAX vaccine-sharing scheme were to arrive in Rwanda on Wednesday, as efforts to inoculate the world's poorest nations accelerate.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.